8 results about "Macula lutea degeneration" patented technology

The present invention relates to peptides that have preventive, ameliorative, or therapeutic effects against amyloidosis and / or macular degeneration, are safe for living organisms, and have few side effects including abnormal reactions, as well as pharmaceutical compositions and health functional foods containing the same.

This invention relates to a kit and method for detecting pathogenic genes of hereditary macular degeneration (AMD). The kit includes a hybridization mixture containing a probe set for detecting AMD pathogenic genes. The probe set includes capture probes capable of simultaneously and specifically capturing pathogenic genes ABCA4, BEST1, PRPH2, ELOVL4, PROM1, IMPG1, IMPG2, EFEMP1, RP1L1, and TIMP3, as well as the pathogenic regions of MCDR3 and MCDR1. The capture probes capturing the pathogenic regions of MCDR3 and MCDR1 include probes with sequences shown in SEQ ID NO. 1-174 and SEQ ID NO. 175-235, respectively. This invention proposes a targeted amplification strategy for the non-coding pathogenic region of NCMD, successfully detecting two novel point mutations and one genomic structural variation, achieving the detection of point mutations and structural variations in non-coding regions.

The present invention relates to a vascular endothelial growth factor (VEGF) inhibitor for use in the treatment of wet macular degeneration, wherein the VEGF inhibitor is adapted to be administered intravitreally to a patient, wherein the patient has previously been treated intravitreally with the VEGF inhibitor for approximately one year, and has one or more genetic variants that are single nucleotide polymorphisms selected from rs2106124, rs1879796, rs12148845, rs12148100, rs17482885, and rs17629019.

Methods of treating ocular diseases (e.g., neovascular age-related macular degeneration, age-related macular degeneration, diabetic macular edema, choroidal neovascularization (including pathologic myopic choroidal neovascularization (mCNV), angiod streaks, choroiditis (including choroiditis secondary to ocular histoplasmosis), idiopathic degenerative myopia, retinal dystrophy, rubeosis iridis, pseudoxanthoma elasticum, and trauma), macular edema following retinal vein occlusion, central retinal vein occlusion, cystoid macular edema, glaucoma (e.g., neovascular glaucoma), polypoidal choroidal vasculopathy, retinopathy of prematurity, ocular von Hippel Lindau disease, diabetic retinopathy, and retinitis pigmentosa) by administering to a human patient an amount and frequency of gomiliximab or a pharmaceutically acceptable salt, solvate, or ester thereof sufficient to treat the ocular disease are provided.

Methods for treatment of damaged corneal endothelium are provided, applicable for treatment or protection of corneal endothelium in various circumstances such as oxidative stress, age-related decline in endothelial cell density, inherited or non-inherited degenerative disease such as Fuchs endothelial corneal dystrophy, surgical trauma, increased intraocular pressure (IOP) or contact lens overuse. Further provided are methods for treatment of retinal degeneration such as in diabetic retinopathy, age-related macular degeneration and glaucoma. The methods comprise the transplantation of viable isolated, exogenous, mitochondria systemically and / or directly to the cornea or the retina.

The present application provides a kind of composition and preparation method and application for preventing cataract, macular lesion and diabetic retinopathy, belong to biological medicine technical field.The composition of the present application includes: nano active ingredient, plant extract, glycyrrhizic acid dipotassium, nicotinamide, taurine, ikdoin, caffeine and lutein;Plant extract is composed of wild chrysanthemum flower extract and gentian extract;Nano active ingredient is composed of nano-encapsulated astaxanthin and nanometer retinol.The composition of the present application effectively inhibits key pathological links such as lens protein oxidative denaturation, retinal pigment epithelial cell function decline and pathological angiogenesis by multi-dimensional synergistic mechanism of antioxidant-anti-inflammatory-vascular protection-metabolic regulation, thereby realizing the prevention and adjuvant therapy effect on three major blinding eye diseases of cataract, age-related macular degeneration and diabetic retinopathy.

This application provides antibody-drug synergistic compounds, compositions, and methods for treating ocular diseases such as dry AMD, GA secondary to AMD, and exudative AMD. The antibody-drug synergistic compounds may include antibodies such as anti-angiogenic antibodies or anti-VEGF antibodies conjugated to small molecule complement inhibitors by a linker, or anti-complement antibodies conjugated to small molecule inhibitors of VEGF, VEGFR, PDGF, PDGFR, FGF, or FGFR by a linker. The linker conjugating the antibody and drug is hydrolyzable over time within the target eye, thereby allowing both the antibody and drug to exert their functions within the target eye. The compounds and compositions can confer superior efficacy compared to either the antibody or the drug alone due to the synergistic effect of the ADS compounds. Methods for treating age-related macular degeneration using ADS compounds and compositions are also provided.

The present invention is directed to compositions for oral administration comprising two or more active ingredients selected from the group consisting of quercetin, metabolites, derivatives and salts and hydrates thereof, a kaempferol rutinoside and salts and hydrates thereof, indole-3-carbinol and derivatives and metabolites and salts and hydrates thereof and gallic acid and salts and hydrates thereof. The present invention is further directed to methods for treating dry eye disease, treating age-related macular degeneration, increasing Bruch's membrane stiffness, modulating expression of a gene selected from the group consisting of YAP, TAZ, integrin α5, integrin β5, interferon β1, interleukin-6, C-X-C motif chemokine ligand 1, C-X-C motif chemokine ligand 10, and combinations thereof, increasing adhesion of retinal pigment epithelium cells to a Bruch's membrane, and methods of modulating a secretory profile of senescent cells exhibiting the senescence-associated secretory phenotype comprising administering an effective amount of one or more active ingredients selected from the group consisting of kaempferol derivatives and salts thereof and hydrates thereof, quercetin metabolites, derivatives and salts and hydrates thereof, indole-3-carbinol and derivatives and metabolites and salts and hydrates thereof and gallic acid and salts and hydrates thereof to a subject in need thereof.